Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 76.13% is in line with its 5-year average of 76.65%, around the middle of its 5-year range (73.01%–79.84%).
0.65% above its 12-month average of 75.64%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 77.61%.
GROSS MARGIN
76.13%
GROSS MARGIN AVG TTM
75.64%
GROSS MARGIN AVG 3Y
75.84%
GROSS MARGIN AVG 5Y
76.65%
GROSS MARGIN AVG 10Y
74.59%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.65%
CURRENT VS 3Y AVG
+0.39%
CURRENT VS 5Y AVG
-0.68%
CURRENT VS 10Y AVG
+2.06%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
+88.53%
vs the sector median at left
Market Cap
$1.84B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.84B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
Market Cap
$1.82B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.86B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
22.32%
5Y Avg
30.29%
Market Cap
$1.79B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novocure Ltd (NVCR) | $1.84B | 76.13% | 75.64% | 75.84% | 76.65% |
| Absci Corporation (ABSI)vs › | $1.84B | -319.36% | -798.46% | -813.46% | -704.28% |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 9.22% | 11.32% | 13.89% | 14.07% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 72.90% | 70.08% | 67.68% | 66.96% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.86B | 0.00% | 0.00% | 22.32% | 30.29% |
| Azenta, Inc. (AZTA)vs › | $1.88B | 44.05% | 44.96% | 41.63% | 40.93% |
| Novavax, Inc. (NVAX)vs › | $1.88B | 93.67% | 81.97% | 61.43% | 74.28% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | 100.00% | 100.00% | 100.00% | 100.00% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | 78.67% | 83.63% | 79.97% | 53.31% |
Gross Margin
76.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 77.61% |
| 2026-03-31 | 77.63% |
| 2025-12-31 | 75.82% |
| 2025-09-30 | 73.25% |
| 2025-06-30 | 73.88% |
| 2025-03-31 | 75.15% |
| 2024-12-31 | 79.25% |
| 2024-09-30 | 77.19% |
| 2024-06-30 | 76.95% |
| 2024-03-31 | 75.68% |
| 2023-12-31 | 75.67% |
| 2023-09-30 | 74.79% |
| 2023-06-30 | 73.01% |
| 2023-03-31 | 75.76% |
| 2022-12-31 | 77.51% |
| 2022-09-30 | 77.29% |
| 2022-06-30 | 79.77% |
| 2022-03-31 | 79.84% |
| 2021-12-31 | 77.71% |
| 2021-09-30 | 77.39% |
| 2021-06-30 | 78.58% |
| 2021-03-31 | 80.41% |
| 2020-12-31 | 80.45% |
| 2020-09-30 | 78.60% |
| 2020-06-30 | 78.03% |
| 2020-03-31 | 75.94% |
| 2019-12-31 | 75.02% |
| 2019-09-30 | 75.13% |
| 2019-06-30 | 75.66% |
| 2019-03-31 | 72.97% |
| 2018-12-31 | 66.95% |
| 2018-09-30 | 70.74% |
| 2018-06-30 | 67.76% |
| 2018-03-31 | 65.01% |
| 2017-12-31 | 70.85% |
| 2017-09-30 | 69.76% |
| 2017-06-30 | 65.73% |
| 2017-03-31 | 66.56% |
| 2016-12-31 | 63.72% |
| 2016-09-30 | 48.70% |
| 2016-06-30 | 9.54% |
| 2016-03-31 | 38.85% |
| 2015-12-31 | 49.09% |
| 2015-09-30 | 36.79% |
| 2015-06-30 | 27.40% |
| 2015-03-31 | 25.17% |
| 2014-12-31 | 30.81% |
| 2014-09-30 | 40.88% |
| 2014-06-30 | 38.31% |
| 2014-03-31 | 28.97% |
